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SIVmac251 challenges, exhibited elite control of viremia over 6.5 years. They were negative for host factors
associated with control of SIV infection. After a third intrarectal challenge with SIVsmE660, all controlled
viremia, with one (macaque #5) maintaining undetectable viremia in blood. Acquisition was not blocked, but
virus was contained in the jejunum and draining lymph nodes. Polyfunctional memory T cell responses and
high-titered neutralizing and non-neutralizing serum and mucosal antibodies were present before and
maintained post-challenge. The level of protection seen for animal #5 was predicted from analyses of gene
transcription in jejunum 2 weeks post-challenge. Macaques #7 and #9, exhibiting lower pre-challenge
cellular and humoral immunity, partially controlled the SIVsmE660 challenge. Initial vaccine-induced control by
macaque #5 extended to the SIVsmE660 challenge due to multiple immunemechanisms that were boosted and
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Identiﬁcation of immune correlates of protection from HIV
infection has proven to be very difﬁcult given the multifaceted nature
of the host immune response and factors associated with viral control
(Deeks and Walker, 2007), as well as the sequence variability of HIV
and its complex life cycle. Natural, elite control of HIV infection is rare.
Initially deﬁned as control of viremia to undetectable levels without
drug therapy, the extent of elite control using highly sensitive PCR
methods has been recently determined as median plasma RNA levels
of 2 copies/ml (Pereyra et al., 2009). Elite controllers are invaluable fordeciphering mechanisms of host immune control of viremia. Multiple
factors have been implicated, including HLA class I alleles B*27 and
B*57 associated with protective CTL responses; the presence of
polyfunctional, mucosal CTLs; enrichment of certain killer cell Ig-like
receptors (KIR) and/or ligands; the presence of viruses with
attenuated replication; a general decrease in levels of immune
activation; and the presence of intracellular host factors that limit
virus replication, such as APOBEC3G and TRIM5α (Baker et al., 2009;
Deeks and Walker, 2007; Ferre et al., 2009; O'Connell et al., 2009;
Prado et al., 2010). HIV-1 neutralizing antibody and antibody
reactivity by Western blot have correlated with lower viral loads in
one cohort of elite controllers (Pereyra et al., 2009), while higher
titers of ADCC antibody have correlated in another (Lambotte et al.,
2009). Despite their best efforts, researchers have been unable to
point to a single deﬁnitive immune correlate shared among all elite
controllers.
Elite control of SIV infection in rhesus macaques has also been
demonstrated (Loffredo et al., 2007; Yant et al., 2006). Most attempts
Fig. 1. Immunization and challenge history of elite controller macaques (31, 40).
(A) Macaques #5, #7, and #9 were originally immunized with an Ad-SIVsmH4 env/rev
recombinant vector and boosted with a conformational CD4 binding site peptomer.
Two priming immunizations given ﬁrst orally and intranasally and second intratrache-
ally were followed by two intramuscular boosts of peptomer in PBS. A high dose
SIVmac251 rectal challenge was administered 6 weeks later. The times of second and
third intrarectal challenges with SIVmac251 and SIVsmE660, respectively, and an
intermediate in vivo CD8 depletion are indicated. (B) SIV RNA copies/ml plasma are
shown for all three macaques, exhibiting elite control of the ﬁrst high dose SIVmac251
rectal challenge and durable protection from an identical, second SIVmac251 rectal
challenge one year later. Control group represents the geometric mean of 8 and 2
control macaques for the ﬁrst and second challenges, respectively. (C) In vivo peripheral
CD8+ T cell depletion resulted in reemergence of virus for macaque #5. Virus remained
undetectable for #7 and #9 (not shown). (D) Outcome of a third heterologous rectal
SIVE660 challenge, 3.5 years after the CD8 depletion study and 8 years since initial
immunization. Macaques 858 and 870 are naïve controls.
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of the MHC class I allele Mamu-B*08 in protection of Indian rhesus
macaques from pathogenic SIVmac239 infection. Fifty percent of all
macaques possessing this allele establish elite control. In one study,
peripheral CD8+ T cells were depleted in macaque elite controllers
and the frequency and speciﬁcity of the CD8+ T cells reappearing
upon control of viremia were evaluated (Friedrich et al., 2007). CD8+ T
cells which recognized epitopes restricted by Mamu-B*08 were
expanded. Upon mutation of associated epitopes and re-infection of
Mamu-B*08 positive macaques, the majority of the mutated viruses
were unable to establish elite control (Valentine et al., 2009). One
cannot discount however the potential role of NK cells in control of
viremia, since they express KIRs that recognize class I ligands. Evidence
of KIR3DL polymorphisms and decline of NK function has been
associated with higher SIV replication in rhesus macaques (Bostik
et al., 2009). Other protective mechanisms may involve CD4+ T cells, as
those isolated from SIV elite controller macaques are able to lyse
infected macrophages in vitro (Sacha et al., 2009).
We have followed three Indian rhesus macaques, which over a
6.5 year period maintained elite control of peak and chronic viremia
after two separate high dose mucosal SIVmac251 challenges. These
macaques are unique in that none of the reported MHC class I or II
alleles associated with elite control or diminished chronic viremia
(Mamu A*01, B*17, B*08, DRB1*0306 and DRB1*1003) (Giraldo-Vela
et al., 2008; Loffredo et al., 2007; Pal et al., 2002; Yant et al., 2006;
Zhang et al., 2002) have been detected. They were originally
immunized with replicating adenovirus type 5 host range mutant
(Ad5hr)-SIVsmH4env/rev and boosted with SIVmac251 peptomer (a
conformational polypeptide composed of 18-mer units representing a
partial sequence of the CD4 binding site) and exhibited elite control of
a subsequent high dose SIVmac251 rectal challenge (Patterson et al.,
2004) (Fig. 1A). Control was achieved not only during the chronic
phase, but also during acute infection. One macaque (#9) showed
complete lack of plasma viremia, one (#7) exhibited a single positive
detection of 500 RNA copies/ml plasma, and the last (#5) displayed
only low level acute viremia (peak of 105 RNA copies) and rapid
clearance by week 6. All macaques were SIV proviral DNA positive at
one or more time points, however. Twelve months later with no
intervening immunization, a second rectal challenge with the same
SIVmac251 virus stock resulted in no detectable acute or chronic
viremia (macaques #7 and #9) or a single detection (macaque #5),
and subsequent durable protection (Malkevitch et al., 2006) (Fig. 1B).
In order to identify the mechanism of elite control, in vivo CD8
depletion experiments were conducted 9 months later. Whereas
viremia rebounded with CD8 depletion and was controlled with
reappearance of CD8 T cells in macaque #5, as shown in blood
(Fig. 1C), lymph node and rectal tissue, viremia was undetectable
throughout the time course for macaques #7 and #9 (Malkevitch
et al., 2006).
A cellular component seemed to be involved in the durable
protection of at least macaque #5. Due to productive virus exposure
after the ﬁrst SIV challenge, macaque #5 showed both Gag- and Env-
speciﬁc cellular immune responses (Malkevitch et al., 2006). However,
high titered SIV gp120 binding antibodies, neutralizing antibody to T-
cell line adapted (TCLA)-SIVmac251 and antibody-dependent cellular
cytotoxicity (ADCC) mediating antibodies were also present. Macaques
#7 and #9 also exhibited cellular responses to Gag and other SIV
antigens before and after the SIVmac251 rechallenge/CD8 depletion, in
spite of their aviremic status, suggesting exposure to viremia below the
detection limit of 50 copies or sequestration of virus at a secondary site.
However, no anti-envelope binding antibody in serum or mucosal
secretions was detected for either macaque #7 or #9.
Overall, no clear immune correlate of protection emerged from
these earlier studies. Therefore, 3.5 years after CD8 depletion and
7.5 years since initial immunization, we rechallenged the macaques
using pathogenic, heterologous SIVsmE660. Our aims were to examinethe extraordinary long-termviremia control exhibitedby themacaques,
evaluating the extent of virus in tissues as well as blood, and to
comprehensively investigate durable immunity and protection using a
spectrum of the newest methods to evaluate cellular, humoral and
mucosal immunity. ExtensiveMHC class I plus TRIM5α genotyping, the
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macaques (Lim et al., 2010), as well as analysis of gene transcriptional
proﬁles in jejunum before and after challenge were performed.
Even though three macaques cannot provide statistical power, the
opportunity to acquire valuable new information regarding elite control
outweighed this concern.Results
SIVsmE660 challenge results
Following SIVsmE660 challenge both naïve control macaques, #858
and #870, became rapidly infected, exhibiting peak viral loads
between 107 and 108 copies/ml plasma. Subsequently over the entire
monitoring period, the viral burdens for both macaques never
dropped below 106 copies/ml. In evaluating viral loads of the elite
controller macaques, ampliﬁcation of the SIVmac251 gag gene by real-
time PCR was not detected in any macaque plasma sample through
week 12 post SIVsmE660 challenge (data not shown). Therefore, plasma
viremia detected by NASBA during this time period is attributed solely
to SIVsmE660. Following intrarectal SIVE660 challenge, macaque #5
continued to exhibit elite control of the heterologous, pathogenic SIV
isolate (Fig. 1D). Viral RNA was undetectable in blood over the entire
time course. Consistent with its lack of viremia, no signiﬁcant drop in
CD3+CD4+ T cells in blood was observed (Supplementary Fig. S1A).
Similarly, a high percentage of CD3+CD4+ T cells was present in
jejunal tissue 2 weeks post-challenge (Supplementary Fig. S1C).
However, these cells declined in BAL implying that virus was present
at a cryptic site (Supplementary Fig. S1B). This was conﬁrmed by the
presence in lymph node of 17,512 and 29,798 viral RNA copies, at
weeks 2 and 36 post-challenge, respectively, (Table 1) using NASBA,
which does not discriminate SIVmac251 and SIVsmE660 gag sequences. A
separate SIVmac251 PCR conﬁrmed reactivated, low level RNA of 1650
and 349 viral copies at weeks 2 and 36 post-challenge, respectively for
animal #5. Thus while undetectable in plasma, both viruses were
detected in the lymph node of macaque #5 post-challenge. In
jejunum, no SIVsmE660 was detected post-challenge, however pre-
challenge, 108 copies of SIVmac239 were detected – 3.5 years after CD8
depletion. Therefore, SIVmac251 originating from the ﬁrst challenge
was present and being controlled at very low levels.
For macaque #9, a 1 log blunting of acute plasma viremia
compared to naïve control macaques was observed. Subsequently,Table 1
Tissue viral loads.
Lymph node
Conserved SIV Gag (copies/μg tissue RNA) SIV251 (copies/μg tissue RNA)
Pre Week 2 Week 36 Pre Week 2 Week 36
5 Neg (I) 17,512 (M) 29,798 (A) Neg 1650 349
7 Neg (I) 21,835 (M) 85,581 (A) Neg Neg Neg
9 Neg (A) 745,813 (M) 16,396 (A) Neg Neg Neg
858 Neg (I) 725,514 (M) 1,216,698 (I) Neg Neg Neg
870 Neg (I) 66,720 (M) 586,948 (I) Neg Neg Neg
Jejunum
SIV239 (copies/μg tissue RNA) SIVE660 (copies/μg tissue RNA)
Pre Week 2 Week 36 Pre Week 2 Week 36
5 108 6356 2400 Neg ND Neg
7 Neg Neg Neg Neg ND Neg
9 Neg Neg Neg Neg ND Neg
858 Neg Neg Neg Neg ND 223
870 Neg Neg Neg Neg ND 20,001
M=mesenteric; A=axillary; I=inguinal.viremia was controlled rapidly by week 10 to around 1000 copies and
became undetectable after week 36 (Fig. 1D). A single viral detection
occurred at week 66, but overall, this macaque exhibited sustained,
strong control out to 74 weeks. The high acute plasma viremia was
reﬂected in a lymph node biopsy, where the viremia level was similar
to controls, but by week 36, the lymph node viral load was reduced
(Table 1). No SIVmac251 virus was detected at any time point. In
accordance with the high acute viremia levels, CD3+CD4+ T cells
dropped in blood, BAL and jejunum (Supplementary Figs. S1B, C), but
thereafter remained stable in blood. Neither SIVmac239 nor SIVsmE660
was detected in jejunum before or after SIVsmE660 challenge (Table 1).
A blunted peak plasma viremia of 2 logs compared to control
macaques was seen for macaque #7 with quick resolution of viremia
by week 6 (Fig. 1D). Viral RNA loads thereafter vacillated broadly
between ≤10,000 copies and undetectable levels until control was
rapidly lost at week 36 (Fig. 1D). Afterwards, viremia continued to rise
and reached control levels, suggesting viral escape by an as yet
undetermined mechanism. Likewise, CD3+CD4+ T cell numbers were
unchanged on average in blood until 28 weeks post-challenge, when a
slow decline was observed (Supplementary Fig. S1A). During the
acute phase (week 2), no drop in CD3+CD4+ T cells was seen in either
BAL or jejunum (Supplementary, Figs. S1B, C), but viremia was
detectable in lymph node at a level comparable to macaque #5
(Table 1). By week 36, virus (presumably SIVsmE660) spiked to
approximately 85,000 copies, similar to the rising plasma levels.
However, SIVsmE660 could not be ampliﬁed from week 36 jejunal
biopsies, although it was readily detected in the control macaques at
the same time point. Unlike macaque #5, SIVmac239 was not seen in
jejunum prior to or after SIVsmE660 challenge.
Cellular immune responses
A battery of cellular immune responses was evaluated in blood and
tissue of these macaques. Gag239- and Env239 (again, closely related to
251)-speciﬁc IFN-γ secreting cells were evaluated by ELISPOT in
freshly prepared peripheral blood lymphocytes. Prior to challenge,
animal #5 exhibited higher levels of Env- and Gag-speciﬁc responses
than #9, whereas macaque #7 showed no SIV-speciﬁc IFN-γ-secreting
cells (Supplementary Fig. S2A). All three elite controllers exhibited
strong T cell proliferative responses pre-challenge which declined
immediately post-challenge, but regained potency by week 12
(Supplementary Fig. S2B). Gp120, p27 and Ald-SIV stimulations all
elicited responses.
Multiparameter ﬂow analysis of Env- and Gag-speciﬁc cytokine
secreting T cells from blood, BAL and jejunal tissues was carried out
using an 11-color antibody panel to distinguish T cell and memory
subsets, as well as IFN-γ, IL-2, and TNF-α cytokines. No virus-speciﬁc
responses were detected for eithermacaque #7 or #9 in PBMC prior to
or following challenge in contrast to macaque #5 which exhibited
broadly reactive cytokine positive responses that were especially
potent among CD4 total memory T cells speciﬁc for both EnvsmH4 and
Gag239 (Fig. 2A). Prior to SIVE660 challenge the Env-speciﬁc CD4
memory T cells recognized EnvsmH4 peptides, representing the env
gene present in the Ad5hr-SIVsmH4env/rev vaccine and not the
envelope matched to the ﬁrst challenge virus, SIVmac251. After
SIVsmE660 challenge however, the response of animal #5 became
broader, with strong, sustained Env speciﬁc responses to Env239
peptides as well. Overall however, the highest frequency of response
prior to and post-challenge was to Gag239 peptides (Fig. 2A) reﬂecting
prior challenge history rather than the vaccination regimen.
The total memory cells in PBMC of macaque #5 were further
examined for polyfunctionality (cells secreting two or three cyto-
kines), reported to correlate with protection (Darrah et al., 2007;
Lindenstrom et al., 2009; Seder et al., 2008). Prior to challenge, up to
65% of EnvsmH4 and 80% Gag239 CD4 total memory cells were
polyfunctional in nature (Fig. 2B) and predominately of a central
Fig. 2. The sum percent of IFN-γ++IL-2++TNF-α+ total memory T cells in PBMCs formacaque #5. (A) Shown are the total cytokine positive cells among total memory CD4 or CD8 T
cells at weeks−2, 2 and 36 post SIVsmE660 challenge after stimulation with three separate peptide pools. (B) Pie charts for each ﬂow sample from panel A, representing the percent
triple, double and single cytokine secreting cells. Neg=negative response.
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memory cells, this polyfunctional response was maintained post-
challenge. Newly expanded CD4 memory cells in response to the
SIVsmE660 challenge included Env239-speciﬁc polyfunctional cells that
persisted to week 36. Interestingly, the CD4 EnvsmH4-speciﬁc memory
cells seemed to evolve functionally post-challenge, and at week 2
during the acute phase displayed an effector-type proﬁle with the
majority secreting only IFN-γ (Fig. 2B).
The CD8 memory T cell response was of low frequency pre-
challenge for macaque #5 and only seen in response to EnvsmH4
stimulation (Fig. 2A). By week 2 however, these cells dramatically
expanded up to 1.4% of total memory T cells, again with an IFN-γ
secreting (Fig. 2B) effector memory phenotype (CD28−CD95+).
Although not detected prior to challenge, CD8 total memory T cell
responses for macaques #7 and #9 were also observed in PBMC post-
challenge. However, the frequency of the responses was low (0.1–
0.2%), and no polyfunctionality was seen (data not shown).
For naïve controls, CD4 and CD8 Gag and Env speciﬁc total memory T
cells were expanded post-challenge with a peak CD4 Gag frequency of
1.5%. The cytokine proﬁle of these memory cells was almost exclusively
TNF-α (data not shown).
In contrast to responses only for animal#5 inperipheral blood, virus-
speciﬁc cellular immune responsesweredetected for all threemacaques
in BAL. Fig. 3A shows the frequency of total cytokine responses among
CD4 and CD8memory T cells formacaques #5, #7 and #9 pre- and post-challenge. As fewer lymphocyteswere isolated from BAL at week 2, Env
and Gag peptide stimulations had to be combined. Therefore, for ease in
interpretation, stimulations shown in Fig. 3A are combined for all time
points. CD4 total memory T cell responses were highest for animal #5
pre-challengewhile responses formacaques #7 and #9were detectable
but low. None of themacaques exhibited post-challenge responses until
week 36when a very high total cytokine responsewas seen among CD4
total memory cells for animal #5 (2.68%) and lesser responses by
macaques #7 (1.5%) and #9 (0.25%). For macaque #5, most of the pre-
challenge CD4+memory T cells were polyfunctional (Fig. 3B), although
compared to blood where the majority were central memory, only 20–
25% were triple positive central memory. The majority were double
positive (IFN-γ+, TNF-α+) effector cells. These T cells disappeared
completely atweek 2, but byweek 36, theywere detected at high levels,
were polyfunctional (Fig. 3B), and both central and effector memory
cells were expanded (data not shown).
CD8 memory cell responses in BAL for all three macaques
displayed a different pattern (Fig. 3A). A relatively high frequency of
cytokine secreting memory cells was exhibited by all animals pre-
challenge (0.4 to 1%). The cells were generally of the expected effector
memory phenotype (not shown). The responses extended to week 2
post-challenge for all three macaques (Fig. 3A) but by week 36 there
was a noticeable decrease in frequency of cytokine secreting cells. At
this time point, most CD8memory T cells of macaque #5 secreted only
IFN-γ (Fig. 3B). Cytokine responses among CD8+ T cells of macaques
Fig. 3. The sum percent of IFN-γ++IL-2++TNF-α+ total memory T cells in BAL samples for macaques #5, #7 and #9 over time. (A) Shown are the total cytokine positive cells
among total memory CD4 or CD8 T cells at weeks −2, 2 and 36 post SIVsmE660 challenge after stimulation with peptide pools noted. Cell numbers were lower at week 2 post-
challenge, so peptide pools were combined for stimulations. For ease in interpretation, responses were summed at weeks−2 and 36 as well. (B) Pie charts for each ﬂow sample from
panel A, representing the percent triple, double and single cytokine secreting cells. Neg=negative response. ND=denotes not done.
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of cytokine secreting T cells in the jejunum for all macaques. Even
post-challenge, negligible responses were seen (data not shown).
Humoral immune responses
Binding antibodies in serum to SIVmac251 gp120 were continually
monitored over the immunization and challenge history of these
macaques. Prior to the ﬁrst SIVmac251 challenge, cross-reactive binding
antibodies to SIVmac251 envelope were elicited by Ad5hr-SIVsmH4env
priming, but were not boosted by the peptomer immunizations
(Fig. 4A). Post-challenge, only macaque #5 showed a dramatic spike
in binding antibody, coinciding with the presence of detectable
viremia in blood. Subsequently, before, during and after the second
and third challenges, high levels of antibody were maintained in
animal #5 (Figs. 4B, C). For macaques #7 and #9, only low titers of 100
were seen post 2nd challenge, but clearly macaque #9 exhibited ananamnestic response within the ﬁrst two weeks after the third
challenge. We believe the apparent drop in binding titer for animal #7
at week 2 may have resulted from an inadvertent switching of sample
aliquots for macaques #7 and #9 at week 1. The binding results were
reproducible, however, for all other humoral assays (ADCC, neutral-
ization, ADCVI, see below) the antibody activity of macaque #9
appeared earlier and at higher titer than for macaque #7, consistent
with a possible switch of the binding assay aliquots. The binding titers
for macaque #7 peaked at week 4 post-challenge, whereas binding
titers of controls were not detectable until this time point.
The original immunization regimen did not elicit neutralizing
antibody against primary SIVmac251 in the three macaques pre-
challenge (Patterson et al., 2004), however all three macaques
exhibited low titer neutralization of TCLA-SIVmac251 before the 1st
challenge which was strongly boosted in macaque #5 but not
macaques #7 and #9 post-SIVmac251 challenge. Macaques #5 and #9
also developed antibodies able to neutralize SIVsmH4 pre-challenge.
Fig. 4. SIVmac251 serum binding antibody titers (log10) throughout the three SIV challenges.
92 L.J. Patterson et al. / Virology 411 (2011) 87–102This activity was strongly boosted in animal #5 post-challenge in
conjunction with its transient plasma viremia, but not in macaque #9
which remained aviremic (Patterson et al., 2004). Here, we examined
whether exposure to the second and/or third challenge viruses
elicited additional neutralizing antibody activities. The virus panel
was expanded to include a primary SIVmac251 pseudovirus and an
uncloned SIVsmE660 virus grown in CEMX174 cells which exhibits tier
2 neutralization in M7-Luc cells. None of the macaques was able to
neutralize SIVsmE660 over the course of immunization and the three
challenges (data not shown). Additionally, the three macaques were
originally boosted with a peptomer mimicking the CD4 binding site of
the virus. Development of anti-CD4 binding site antibodies and their
binding to this site could have caused a conformational change in the
envelope leading to antibody development against a CD4-induced siteFig. 5.Neutralizing antibody titers in plasma after SIVsmE660 challenge. Neutralization titers to
HIV-2 without sCD4 added (C) and with sCD4 added (D). In (A), neutralizing titers for macon the virus. Although not deﬁnitive, we included HIV-2 virus with
and without the addition of soluble CD4 as described (Decker et al.,
2005) to assess this possibility.
Only macaque #5 exhibited neutralizing antibody to all viruses
tested except SIVsmE660 prior to the heterologous challenge (Fig. 5). In
keeping with its subsequent aviremic status, the titers observed were
maintained at constant levels post-challenge. High titers were seen
against TCLA-SIVmac251 (Fig. 5A) and HIV-2without sCD4 (Fig. 5C) and
even higher titers against HIV-2 in the presence of sCD4 (Fig. 5D).
Albeit at low level, difﬁcult to neutralize primary SIVmac251 was
neutralized by sera of macaque #5 and an anamnestic response was
exhibited post-challenge (Fig. 5B). Although macaques #7 and #9
were negative for neutralizing antibody activity prior to the SIVsmE660
challenge, both exhibited anamnestic neutralizing responses post-(A) TCLA-SIV mac251 and (B) primary SIVmac251. CD4-induced antibody neutralization of
aque #5 were N4.4×104 at all time points.
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without sCD4 (Figs. 5C, D), but remained negative against primary
SIVmac251 pseudovirus (Fig. 5B) and SIVsmE660 (data not shown).
Non-neutralizing antibodies have been shown repeatedly in our
laboratory to be correlated with control of SIV and SHIV infection in
the rhesus macaque model (Florese et al., 2009; Gomez-Roman et al.,
2005; Hidajat et al., 2009; Xiao et al., 2010). We therefore evaluated
sera of the 3 macaques for antibodies able to mediate ADCC, an
activity requiring interaction between effector cells, SIV-speciﬁc
serum, and target cells expressing SIV antigen. Macaque #5 displayed
potent antibody mediating ADCC against CEM-NKR target cells coated
with both SIVmac251 gp120 (Fig. 6A) and SIVsmE660 gp120 (Fig. 6B)
prior to challenge. Similarly to its binding and neutralizing antibody
activities, ADCC titers were maintained post-challenge. In contrast,
sera of macaques #7 and #9 were negative before challenge, but
exhibited anamnestic responses in ADCC activity against SIVmac251 or
SIVsmE660 by week 2 post-SIVsmE660 challenge.
ADCVI has also been associated with control of viremia (Florese et
al., 2009; Forthal et al., 2006; Hidajat et al., 2009; Xiao et al., 2010).
Here, the threemacaques exhibited a pattern of ADCVI activity similar
to that seen for ADCC (Fig. 6C). Serum of macaque #5 was positive for
ADCVI pre-SIVE660 challenge and the activity was sustained post-
challenge. In contrast, macaques #7 and#9 were negative prior to
challenge but developed strong anamnestic responses by week 2
which peaked at 60% and 50% inhibition respectively. Only low level
ADCVI activity developed in controls over weeks 4 to 12.
Given the macaques' history of vaccination with Env immunogens,
multiple challenges, and their years of elite control, we expected they
would have developedmemory B cells associated with their sustained
antibody and/or anamnestic responses. Therefore, bone marrow cells
obtained atweek25post-challengewere evaluated formemory B cells.
Prior to polyclonal stimulation, animal #5 exhibited the highest level of
Env-speciﬁc IgG memory B cells compared to the other macaques
(Supplementary Fig. S3). The day 0 values represent primarily plasmaFig. 6. Non-neutralizing antibody titers in plasma after SIVsmE660 challenge. ADCC titers of pla
SIVsmE660 infection of rhesus PBMC using plasma diluted 1:200.cells in bone marrow which secrete low levels of antibody. Following
3 days of polyclonal stimulation, Env-speciﬁc ASC increased in all
macaques. Again, the highest level was seen for macaque #5. This
increase is attributed to memory B cells which differentiated in vitro
into short-term plasma blasts or plasma cells. The increase in ASC in
control macaque #858 indicates a cross-reactivity between the
SIVmac251 gp120 used in the ELISPOT assay and the Env of the SIVsmE660
challenge stock.
Mucosal immune responses
The three macaques were originally immunized with replicating
Ad-recombinants which target mucosal epithelium, and subsequent
challenges were mucosally administered. Therefore, it was prudent to
assess induction of SIV-speciﬁc binding antibodies in rectal secretions
(Figs. 7A, B). Only macaque #5 showed measurable anti-Env IgG
speciﬁc activity before challenge. While all 3 macaques displayed
anamnestic responses in rectal IgG and/or IgA binding antibodies, the
IgA responsewas ﬁrst apparent inmacaque #5. Macaque #9 exhibited
both IgG and IgA anamnestic binding antibody responses, whereas
macaque #7 lacked an IgA response.
To assess functional activity of the rectal antibodies, their ability to
inhibit transcytosis of SIVsmE660 and SIVmac251 across tight intestinal
epithelial cell barriers was evaluated. Rectal secretion of macaque #5
was able to inhibit transcytosis of both SIVmac251 and SIVsmE660 at
2 weeks post-challenge (Figs. 7C, D). Rectal antibody of macaque #9
also inhibited SIVsmE660 transcytosis at week 2 post-challenge,
whereas rectal antibodies of #7 did not exhibit inhibition above
levels seen in control animals.
Rhesus macaque microarray
To obtain a more comprehensive view of responses associated
with elite control, we examined the transcriptional proﬁle of genes insma using SIV251 gp120- (A) and SIVsmE660 gp120-coated target cells (B). (C) % ADCVI of
Fig. 7. Mucosal antibody binding titers and transcytosis inhibition by rectal secretions post SIVsmE660 challenge. SIVmac251 Env speciﬁc IgG (A) and IgA (B) titers shown as speciﬁc
activity values (ratio of speciﬁc divided by total IgG or IgA in each sample). Transcytosis inhibition of SIVmac251 (C) and SIVsmE660 (D) across a tight epithelial cell barrier.
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made two separate ways. First, a “fold-change” in gene expression in
comparison to a pre-challenge baseline was performed. Baseline
samples included the two naïve macaques #858 and #870, in addition
to macaques #7 and #9, since statistically they were not different
from naives, and unlike macaque #5, remained essentially aviremic
for approximately 7 years before the 3rd challenge. Finally, the greater
number of animals included in the baseline allowed for greater
statistical power for analyses. Macaque #5 was excluded from the
baseline group since it exhibited signiﬁcant differences in gene
expression at the pre-challenge time point compared to samples from
the other macaques. Fig. 8A summarizes signiﬁcant upregulation in all
three macaques of genes involved in barrier integrity and epithelial
repair and regeneration, a known hallmark for protection from SIV
infection in rhesus macaques (George et al., 2003, 2005). Only
macaque #5 displayed signiﬁcant upregulation of immune response
genes, however, including those associated with innate immunity,
antigen presentation, chemotaxis and interferon induction (Fig. 8B).
The latter upregulation was lower compared to that for the control
macaques, where levels were 30× higher. Most importantly, genes
associated with humoral immunity, including Ig lamba chain, were
highly upregulated in macaque #5, hinting at a mechanism of
protection seen at the gene, protein, and functional level.
Secondly, gene expression in jejunal tissues of all ﬁve macaques
2 weeks post-challenge was also examined. A comparison of macaque
#5 to both naïve animals is shown in Fig. 9 with genes of interest
highlighted in red. Within this box, 1410 genes were signiﬁcantly
different, with relevant pathways listed to the right. Again, genes
involved in immune responses such as T cell receptor signaling, B
cell development and MHC Class I antigen presentation were all
upregulated inmacaque #5, as well asWnt/B-catenin signaling, which
includes genes that downstream can be responsible for epithelial
regeneration, cell development and repair. In turn, innate immune
responses such as NF-kB signaling were comparatively downregu-
lated for macaque #5. Finally, a preliminary comparison of macaque#5 withmacaques #7 and #9 revealed signiﬁcant differences for 6852
genes at week 2 post-challenge, none of which however, included
immune response genes (data not shown). While beyond the scope of
this study, detailed data analyseswill need to be performed in order to
tease out relevant pathways.
MHC class I and TRIM5α genotyping
A thorough examination of rhesus macaque MHC class I genotyp-
ing using 454 deep sequencing (Wiseman et al., 2009) was performed
for all macaques in this study (Supplementary Fig. S4). None were
Mamu A*01 positive and results conﬁrmed the lack of Mamu B alleles
(B*008 or B*017) known to be associated with control of SIV
replication (Loffredo et al., 2007; Yant et al., 2006).
The existence of speciﬁc TRIM5α allele polymorphisms were
shown recently to have an attenuating affect on SIVmac251 replication
in rhesus macaques (Lim et al., 2010). More directly applicable to this
study, three TRIM5 alleles, TFP, Q and CypAwere recently identiﬁed as
correlating with viral outcome from a clonal SIVsmE543 challenge in
rhesus macaques (Kirmaier et al., 2010). While still unproven for the
closely related SIVsmE660 swarm used here (a single rhesus #E660
passage from original RM#E543), animals that were homozygous Q/Q
were most permissive for SIVsmE543 infection, while TFP/TFP, TFP/
CypA, and CypA/CypA macaques were more resistant. Retrospective
typing of macaques used in this study showed that they were
heterozygous for TRIM5 alleles TFP and Q, except for the control naïve
macaque #870 which was homozygous Q/Q (data not shown). Higher
viral loads were not seen for #870 in comparison to the heterozygous
TFP/Q control macaque #858 (Fig. 1C), however. The strong control of
viremia observed for the elite controllers (7-log reduction compared
to controls) argues against TRIM5 alleles being the sole mediator of
control here. Previously, viremia differences of approximately 3 logs
between TFP/TFP and Q/Q macaques following SIVsm543 infection
were seen, while heterozygotes displayed lesser differences. However,
we can't discount that the TRIM5 haplotype exerted some effect.
Fig. 8. Transcriptional proﬁle of jejunal biopsies week 2 post-challenge. (A) Upregulated genes involved in barrier integrity, epithelial repair and regeneration. (B) Upregulated
immune response genes for macaque #5.
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Fig. 9. Changes in gene expression levels in jejunal tissue in vaccinated and control macaques 2 weeks post SIVsmE660 challenge. (A) Heat diagram of changes in gene expression in
each vaccinated animal as compared to control animals (#858 and #870) following SIVsmE660 challenge. Relative increase (red) or decrease (green) of mRNA levels are shown. (B)
Following hierarchical clustering, gene expression levels for the elite controller macaque #5 were then compared to the two control macaques (genes within red box). Pathways
statistically over represented in the gene lists are shown to the right of the red arrow with the genes and P value indicated.
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The goal of this study was to comprehensively assess the level of
viral control and virus induced immunity after a third, heterologous
high dose mucosal SIV challenge in three rhesus macaque elite
controllers. In contrast to other elite controller macaques studied, our
macaques were unique in possessing noMHC haplotypes and TRIM5α
polymorphisms known to be associated with elite control. Even given
the complicated immunization/challenge history of these macaques,
they provide an opportunity to undercover alternative, non-MHC-
restricted immune responses associated with protection. The myriad
array of positive immune responses we observed in these macaques
points to multiple immune protective mechanisms, especially potent
humoral immunity. Coupled with comprehensive assessments of
viremia throughout the body and mucosal gene transcription, this
study has implicated a broad range of factors involved in the
maintenance of strong viremia control.
Of the three original macaques, only macaque #5 continued to
maintain strict, elite control, as deﬁned by undetectable plasma
viremia, of the heterologous SIVsmE660 mucosal challenge. However,
examination of viral loads in mesenteric and axillary lymph nodes
showed that this macaque, while negative pre-challenge, became
infected. Both SIVsmE660 and SIVmac251, reactivated at low level from
previous exposures, were undetected in blood, but present andcontained locally in the lymph node (Table 1). When SIV is
administered across a mucosal barrier, virus establishes an initial
localized infection in a small number of cells, the founder population
(Li et al., 2005; Miller et al., 2005). Dissemination to draining lymph
nodes can occur within 24 h, but until viremia hits a threshold level in
the mucosa – usually 5–6 days – viremia in the distal sites and
periphery is unsustainable. We did not assess the level of viremia at
the rectal mucosa, the site of mucosal challenge, but SIVsmE660 was
disseminated to draining lymph nodes and remarkably, subsequently
contained. This control of viremia was mediated at the local site of
infection, in the lymph node itself, or at both sites.
It was surprising that before rechallenge, a low level SIVmac251
infection (108 copies) was detected in the jejunummore than 3 years
after CD8 depletion and reappearance of viremia in macaque #5
(Table 1). Interestingly, SIVsmE660 was never detected in the jejunum,
although a critical 2-week timepoint could not be evaluated due to
lack of sufﬁcient sample. However, the original SIVmac251 infection
was reactivated in the jejunum following SIVE660 challenge, increased
10-fold, and thereafter remained stable. To our knowledge, this is the
ﬁrst detection of long term viremia sequestration and control at a
mucosal site. Whatever the mechanism(s) of mucosal immune
control, it did not prevent SIVE660 acquisition. Nevertheless, SIVE660
replication was subsequently controlled in the lymph node to a level
that precluded spread of viremia to the blood over the entire post-
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suppressors, low level, ongoing viral replication did not reseed the
latent reservoir, and most likely originated from an as yet unknown
cryptic reservoir (O'Connell et al., 2010). It is known that upon
removal of HAART therapy and necropsy of SIV-infected rhesus
macaques, virus can be detected in numerous tissue sanctuaries, in
particular lymph nodes, spleen, and gastrointestinal sites (North et al.,
2010), similar to sites where viremia was detected here. While we
have learned much regarding initial viral infection at mucosal sites
and its eventual systemic spread, greater understanding of the
immune processes that contain it mucosally and control its dissem-
ination is needed.
In spite of the strong control of SIVmac251 in jejunal tissue and the
inability to detect SIVE660 at that site, we were not able to associate
local cellular immune responses with viremia control. Virus-speciﬁc
responses in the jejunum were consistently negative by intracellular
cytokine staining. Continued stimulation by the low level viremia at
this mucosal effector site might have resulted in already highly
activated cells becoming anergic and unresponsive to further in vitro
stimulation. However, in a study in which a large amount of jejunal
tissue was obtained for analysis by necropsy of macaques immunized
with live attenuated virus, cytokine secreting cells were correlated
with protection (Genesca et al., 2008). Furthermore, a recent study in
which virus-speciﬁc effector cells were visualized in situ (Li et al.,
2009) supports the notion that these cells exist at this site. We may
have missed detection of cytokine-positive cells due to sampling
issues. Alternatively, other mechanisms may have played a role in the
protection observed.
In contrast to results obtained with jejunal tissue, macaque #5
exhibited outstanding cellular immune responses in terms of breadth
and frequency, particularly in blood and BAL. SIV-speciﬁc IFN-γ
secreting PBMC in addition to broad, potent T cell proliferative
responses existed prior to SIVE660 challenge and were maintained
throughout the post-challenge phase. Polyfunctional, CD4 and CD8
central and effector memory cells speciﬁc for both Env and Gag were
present at extremely high frequency pre-challenge and were boosted
post-challenge in both peripheral blood and BAL (Figs. 2, 3). The
expansion post-challenge of vaccine-speciﬁc EnvsmH4 CD4 memory
cells in PBMC to an effector phenotype during the acute phase of
infection followed by contraction during set point to polyfunctional
cells (Fig. 2B) is of note. The complex nature of viremia control in
macaque #5 makes deﬁnitive conclusions difﬁcult, but these effector
cells may have been contributing to control of SIVE660 infection,
especially if they homed back to the rectal mucosa. The concomitant
disappearance of CD4 memory cells from the lung at week 2 (Fig. 3A)
could also have provided for a transient inﬂux of effector cells to the
rectal mucosa. Vaccine elicited effector memory T cell responses have
recently been shown to be associated with protection from SIV
mucosal challenge (Hansen et al., 2009).
Macaques #9 and #7 exhibited lesser control of SIVsmE660 viremia
in comparison to macaque #5, although both showed blunted acute
viremia and subsequent control to undetectable levels during chronic
infection. Macaque #7 rapidly controlled viremia by week 6 and
maintained this control until week 36 when a sharp increase in viral
load indicated immune escape. We plan to sequence viruses around
this time point after single genome ampliﬁcation in order to
determine if a recombination event occurred and shed light on a
possible mechanism of escape. The kinetics of viremia control for
animal #9 differed. This macaque exhibited undetectable viremia
beginning at week 36, however, after week 75 viral loads became
positive and increased slowly (data not shown). Therefore, escape
from immune control may be occurring for this macaque as well.
SIVmac251 was never detected before or after SIVsmE660 challenge in
plasma or tissues of either of these macaques. Unlike animal #5, both
macaques controlled the early SIVmac251 challenges to undetectable
levels and therefore were not exposed to transient SIVmac251 viremia.We speculate that the low-level SIVmac251 infection of macaque #5,
kept under control by potent immune responses, may be playing a
signiﬁcant role in its maintenance of stronger viremia control by
providing a persistent immunologic stimulus.
Although macaques #7 and #9 lacked SIV-speciﬁc cells in PBMC
pre- or post-SIVsmE660 challenge, both macaques displayed pre-
existing virus speciﬁc memory cells in BAL which were boosted
following SIVsmE660 exposure. Since we consistently detected SIV-
speciﬁc CD8+ effector cells at this site for all three macaques, we
speculate that long term memory cells might reside in the upper
respiratory tract (URT), possibly in the lymph nodes draining the
lungs. Our Ad5hr-SIV recombinant vaccines replicate in the URT after
intranasal/intratracheal immunization in the rhesus macaque model.
Therefore, it is likely that durable vaccine-induced immune cells
would reside there.
Functionally diverse, mucosal and plasma antibody responses
were uniquely observed here for all macaques, but especially for #5.
Macaque #5 exhibited serum antibodies able to mediate multiple
activities prior to SIVE660 challenge. The antibodies, both binding and
neutralizing, were generally of high titer and were maintained post-
challenge. In addition to neutralization of primary and TCLA-SIV, sera
of macaque #5 neutralized HIV-2, with enhanced titers seen with
addition of sCD4, implying recognition of CD4-induced epitopes. As
SIVsmE660 was not neutralized, activitiesmediated by non-neutralizing
antibodies such as ADCC and ADCVI were assessed. Both activities
were mediated by sera of macaque #5, and both have been correlated
with reduced viremia (Gomez-Roman et al., 2005; Xiao et al., 2010).
Most of these functional antibody activities were detected post-
challenge for both macaques #9 and #7 too, albeit at lower levels.
Macaque #9 showed more potent SIVsmE660-speciﬁc ADCVI activity
and a more rapid SIVE660-speciﬁc ADCC anamnestic response than #7,
which may have contributed to the better viremia control of this
macaque during chronic infection.
IgG memory B cells speciﬁc for SIV Env were present in bone
marrow of all three macaques, indicative of their long vaccination and
challenge history. Macaque #5 again exhibited the highest levels.
With regard to mucosal antibody, anamnestic SIV Env-speciﬁc IgG
responses were seen for all three macaques, and IgA responses for
macaques #5 and #9. Again, macaque #5 had the highest rectal
antibody levels. Themucosal antibodies elicitedmediated transcytosis
inhibition against SIVmac251 (macaque #5) and SIVsmE660 (macaques
#5 and #9). Inhibition of transcytosis has been associated with
protection both in macaques (Hidajat et al., 2009; Xiao et al., 2010)
and in humans (Devito et al., 2000; Shen et al., 2010). We have
observed that transcytosis inhibitory activity is signiﬁcantly correlat-
ed with reduced chronic viremia in the SHIV89.6P rhesus macaque
model (Xiao et al., 2010) suggesting that it might not only be
important in protecting against acquisition, but might also play a role
in protection against cell to cell transmission. This would be relevant
here regarding control of viremia at tissue sites.
The evaluation by microarray of intestinal gene expression over
time has provided a number of novel observations. Firstly, humoral
immune response genes at this site were upregulated post virus
exposure for macaque #5. Although we detected mucosal antibodies
in rectal secretions, we can now link these functional responses to
gene expression directly after virus exposure since transcriptional
analysis was performed at week 2 post-challenge.
Secondly, numerous genes involved in induction of immune
responses were upregulated in macaque #5 immediately following
challenge. These were related to processes such as innate immunity,
antigen presentation, chemotaxis and T cell responses. A lesser
upregulation of inﬂammatory response genes, in particular interferon
known to be induced to high levels in SIV unprotected macaques
(Bosinger et al., 2009), was observed for macaque #5. In addition,
tight junction and epithelial repair and regeneration genes associated
with protection from SIV infection (George et al., 2003, 2005) were
98 L.J. Patterson et al. / Virology 411 (2011) 87–102upregulated in all three macaques, but more so for macaque #5,
reﬂecting greater control of viremia. Further post-challenge analysis
of clear differences seen between the elite controller macaque #5 and
macaques #7 and #9, which did not control viremia to undetectable
levels, might in the future, yield new clues to SIV protection in the
rhesus macaque model.
It is likely that the stronger protection seen in macaque #5 resulted
in part from the cryptic exposure to SIVmac251. In this animal, vaccine-
elicited anti-envelope antibody was boosted by exposure to SIVmac251
and also augmented by development of anti-gag cellular responses. The
resultant local containment of virus by potent immunity had the
effect of creating a “live-attenuated virus” from thepathogenic SIVmac251
challenges, leading to subsequent complete protection against the
heterologous SIVsmE660. In contrast, macaques #7 and #9, originally
better protected and not subjected to transient SIVmac251 viremia,
initially controlled, but laterwere less able to sustain SIVsmE660 control. A
key difference was their lack of long termmaintenance of a potent anti-
envelope antibody response. The peptomer, administered without an
adjuvant to all three,was not a good booster immunogen in comparison
to SIV envelope itself, and induced only low-titer antibodies at the time
of theﬁrst SIVmac251 challenge.Whether a vaccine regimen thatprovides
better initial anti-envelope boosting and maintenance of high-titer,
functional antibodies will preclude the necessity for continuous, cryptic
antigen exposure will require further investigation. The mechanism by
which macaque #7 lost viremia control is also worthy of pursuit, and
should elucidate whether the initial control was primarily cellular or
humoral.
Overall, the study of the three elite controller macaques has
attributed the potent viremia control to multifunctional cellular,
humoral, and mucosal immune responses. This extraordinary level of
control appropriatelymatches the complex nature of SIV infection and
pathology.
Materials and methods
Animals, viruses and reagents
In addition to the 3 elite controller macaques, 2 naïve rhesus
macaques, #858 and #870, negative for prior exposure to SIV, simian
retrovirus type D, and simian T-cell leukemia virus, served as controls
for the SIVsmE660 challenge. All macaques were housed and main-
tained according to NIH guidelines.
The SIVsmE660 challenge stock was used undiluted (Hirsch and
Johnson, 1994). Intrarectal administration of undiluted stock previ-
ously infected 100% (4/4) of naive macaques, whereas a 1:10 dilution
was not infectious by this route in 4 macaques.
Expression and puriﬁcation of SIVsmE660 gp120 protein was
accomplished as follows. The gp120 gene was optimized using
human codon bias and synthesized by Geneart AG (Regensburg,
Germany). The gp120 gene was cloned into the mammalian
expression plasmid pJWIRES Puro in frame with the tissue plasmin-
ogen activator (tPa) signal peptidewhich replaced the relatively weak
native signal peptide, residues M1–C22, in order to improve secretion
efﬁciency of the mature gp120 protein. A termination signal was
included after R533, at the native cleavage site. Production of the
gp120 was driven by the cytomegalovirus (CMV) immediate early
promoter. The pJWIRES Puro vector contains the puromycin acetyl-
transferase (PAC) gene for selection of stable transfectants in the
presence of puromycin. The PAC gene is linked to the gp120 gene on
the bicistronic RNA via an internal ribosomal entry site (IRES). 293H
cells were transfected with pJWIRES using Lipofectamine 2000 and
the cells were plated and grown under selection with puromycin.
High gp120 expressing cell lines were expanded and gp120 was
puriﬁed from culture supernatants by loading onto a GNL column and
eluting with 0.4 M methyl alpha-D-mannopyranoside in PBS. The UV
peak was concentrated in Vivaspin 30 K MWCO tubes, acidiﬁed to pH4 and passed through a C18 column. Fractions were collected over a 0–
100% acetonitrile in 0.1% TFA gradient. The puriﬁed gp120 was
lyophilized, resuspended in PBS, and frozen at −70 °C.
Sample collection
Lymphocytes were isolated from fresh blood using Ficoll-Paque
Plus (GE), and used fresh or else resuspended in FBS+7% DMSO and
stored in liquid nitrogen for later use. Serum and rectal secretions
were serially collected and stored at−70 °C. Before use in functional
assays, serum samples were thawed at room temperature, diluted 10-
fold with R-10 medium (RPMI 1640 containing 10% FCS, 2 mM L-
glutamine, and pen-strep), and heat inactivated at 56 °C for 30 min.
Rectal secretions were obtained using cotton-tipped swabs and placed
in 1 ml of PBS containing 0.1% bovine serum albumin, 0.01%
thimerosal, and 750 Kallikrein inhibitor units of aprotinin. The
samples were tested for blood contamination using Chemstrips 4
(Boehringer-Mannheim); samples testing positive were not analyzed.
For assay, rectal secretions were thawed, pelleted, and the superna-
tant passed through a 0.45 μm SPIN-X tube (Corning Inc.). Broncho-
alveolar lavage (BAL), lymph node (mesenteric, axillary, and/or
inguinal), and jejunal strip biopsy samples were collected and
processed as previously described (Hidajat et al., 2009; Malkevitch
et al., 2006). Lymphocytes were isolated from BAL and jejunal biopsies
using a percoll gradient of 35% and 65% layered solutions. Lympho-
cytes from lymph nodes were used directly in assays. Separate frozen
lymph node (mesenteric, axillary, inguinal) and jejunal samples were
used for viral RNA determination and for microarray analysis.
Viral load measurement by NASBA
Nucleic acid sequence based ampliﬁcation (NASBA) sensitive to
b50 SIV copies/ml, was utilized to quantitate viral loads in blood and
lymph node samples (Lee et al., 2010; Romano et al., 2000). Primers
were speciﬁc for a conserved sequence in the Gag gene, therefore
discrimination of SIVmac251 and SIVsmE660 was not possible with this
assay.
Quantitative real time RT-PCR
In order to discriminate between SIVmac251 and SIVsmE660 viral burdens
in rhesus plasma, lymph nodes and jejunal tissue, two Gag strain-speciﬁc
quantitative real-time RT-PCR (qRT-PCR) assays were adapted from
previously publishedmethods (Leutenegger et al., 2001; Yeh et al., 2009).
Viral RNAwas extracted and puriﬁed fromplasma and/or tissue using the
QIAmp viral RNA minikit (Qiagen, Valencia, CA). 0.5 μg RNA was then
reverse transcribed using a high capacity cDNA reverse transcriptase kit
(Applied Biosystems, Foster City, CA) using a gag RT primer 5′
GGTGCAGCAAATCCTCT 3′ to generate a cDNA product suitable for future
quantitative PCR. The PCR reaction mixture included (1×) TaqMan®Uni-
versal PCR master mix (Applied Biosystems, Foster City, CA), 200 nM
forward/reverse primers, 250 nM probe and 25 μl cDNA template. cDNAs
were subsequently ampliﬁed using either SIVsmE660 or SIVmac251 gag
primer-probe sets as follows: SIVsmE660 gag forward primer; 5′
CAAGGGTCTGGGTATGAATCC 3′, reverse primer; 5′ TCAATGCTTCTGC-
CATTAATCTAG 3′, probe; 5′ (FAM) TCCTGGCCCTCCTATTCCCTGACA
(BHQ-1) 3′. SIVmac251 gag forward primer; 5′ GCCAGGATTTCAGGCACTGT
3′, reverse primer; 5′ GCTTGATGGTCTCCCACACAA 3′, probe; 5′ (FAM)
AAGGTTGCACCCCCTATGACATTAATCAGATGT (BHQ-1) 3′. Note, for jeju-
nal tissue only, primers speciﬁc for SIVmac239 gag (closely related sequence
to 251), were used as follows: SIV239 gag forward primer; 5′ GCCAG-
GATTTCAGGCACTGT 3′; reverse primer; 5′ GCTTGATGGTCTCCCACACAA
3′; probe; 5′ (FAM) AAGGTTGCACCCCCTATGACATTAATCAGATGTTA
(BHQ-1) 3′. Probes were labeled with a 6-carboxyﬂuorescein (FAM) and
quencher dye BHQ-1 (Integrated DNA technologies Coralville, IA). A
ﬂuorescent signalwas detected by theABI Prism7000 sequence detection
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SIVsmE660 were 2 min at 50 °C, 10 min at 90 °C, followed by 40 cycles of
30 s at 90 °C and 1 min at 63 °C. For SIVmac251 and SIV mac239, cycling
conditions were: 2 min at 50 °C, 10 min at 90 °C, followed by 40 cycles of
15 s at 95 °C and 1 min at 60 °C. Duplicate or triplicate test reactionswere
performed for each sample. Dilutions of RNA standards were used to
extrapolate SIV viral RNA copies/ml. The sensitivity for detection of
SIVmac251 gag was 222 copies, SIVmac239 gag was 90 copies, while for
SIVsmE660 gag it was 115 copy eq/ml plasma.
ELISpot and T cell proliferation assays
SIV-speciﬁc interferon-gamma (IFN-γ) secreting cells were mea-
sured using freshly isolated PBMC after stimulation with SIV Gag239,
Env239, or EnvsmH4 overlapping peptide pools using an ELISpot assay
as described (Malkevitch et al., 2006; Patterson et al., 2003). Mean
spot forming cells (SFC) from triplicate determinations are reported as
SFC/106 PBMC following subtraction of background spots.
T cell proliferative responses to puriﬁed proteins including SIV251
gp120, SIV239 p27 and aldrithiol-2-inactivated SIVmac239 (Ald-SIV)
were assessed in fresh PBMC by 3H-thymidine incorporation as
described previously (Patterson et al., 2008). Samples were assayed in
triplicate, and the stimulation index (SI) was calculated as the mean
counts per minute (cpm) for the stimulated wells divided by the
mean cpm for the R10 or microvesicle control wells.
Intracellular cytokine staining
Intracellular cytokine staining was utilized to measure SIV-speciﬁc
IFN-γ, IL-2, and TNF-α cytokine secreting cells among freshly isolated
PBMC and lymphocytes from BAL and jejunal strip biopsies. A total of
1–2×106 freshly isolated lymphocytes in 400 μl R10 from each tissue
were stimulated with peptides at a 2 μg/ml ﬁnal concentration. SIV
peptide pools were made up of 15-mers overlapping by 11 amino
acids and included EnvsmH4 (Advanced BioScience Laboratories, Inc.,
Kensington, MD), Env239, and Gag239 (AIDS Research Reference and
Reagent Program, NIAID). Control tubes included a non-stimulated
and an SEB (1 μg/ml) positive control. Anti-CD28-Alexa 680 (custom
conjugate), and anti CD49d (BD Biosciences), were also added during
stimulation along with brefeldin A inhibitor (BD Biosciences), all at
the 10 μg/ml ﬁnal concentration. Tubes were incubated at 37 °C for
6 h. Thirty minutes before the 6 hour incubation was over, anti-CCR7-
Paciﬁc Blue (R&D Systems) was added. Cells were washed twice with
PBS, resuspended in 95 μl of PBS plus 5 μl of Aqua Blue viability dye
(Invitrogen, 1:40 dilution of DMSO stock) and incubated at room
temperature (RT) for 10 min. Cells were washed once with PBS, and
surface stained for 20 min at RT with the following antibodies: CD4-
Qdot605 (Invitrogen), CD8-Qdot655 (Invitrogen), CD95-APC (BD
Pharmingen) and CD45RA-ECD (Immunotech) at concentrations
determined by dilution of stock or product insert. Cells were washed
twice, resuspended in 250 μl ﬁx/perm solution (BD Biosciences) for
20 min at 4 °C, washed twice with BDwash buffer and resuspended in
100 μl wash buffer plus the following antibodies: CD3-APC-Cy7, IFN-
γ-FITC, IL-2-PE and TNF-α-PE Cy7 (BD Pharmingen). After 20 min
incubation at 4 °C in the dark, the cells were washed twice with BD
wash buffer and pellets were resuspended in 1% formaldehyde
solution (Tousimis) for acquisition on an LSR II. Approximately one
million lymphocytes were collected for PBMC samples, and 30,000–
100,000 for tissue. Compensation was performed using the same
antibodies bound to BD CompBeads. A singlet, followed by live/dead
and then lymphocytic gates were ﬁrst applied. CD3+ T cells were
divided into CD4 and CD8 populations and for each, CD45RA+CD95+
and CD45RA−CD95+ cells were further subdivided into CD28+CD95+
central and CD28−CD95+ effector memory cells. Percent cytokine
secreting cells among eachmemory subset was then determined. Data
were analyzed using FloJo software (TreeStar Inc., Ashland, OR) andPestle and Spice (version 4.2.2) programs (Mario Roederer, VRC,
NIAID).
Binding and neutralizing antibody assays
Serum binding antibodies reactive with SIVmac251 gp120 Env
protein were measured in an ELISA assay as previously described
(Buge et al., 1997). The reciprocal of the dilution at which the
absorbance was two times greater than a 1:50 dilution of the control
serum was deﬁned as the antibody titer.
Neutralizing antibody titers for the primary SIVmac251 CS.41
pseudovirus were determined using the TZM-bl Luc cell line as
previously described (Monteﬁori, 2004). For TCLA-SIVmac251 and
-SIVsmE660 (H9 and CEM×174-grown respectively), neutralizing titers
were obtained using M7-Luc cells (Monteﬁori, 2004). Titers are
deﬁned as the reciprocal plasma dilution at which there was a 50%
reduction in relative luminescence units (RLUs) compared to virus
control wells which contained no test sample.
CD4-induced neutralizing antibodies (CD4i Nabs) were assayed
using the HIV-2 strain 7312A as described (Decker et al., 2005).
Brieﬂy, the HIV-2 proviral clone pJK7312A (GeneBank/EMBL/DDBJ
accession no. L36874) was transfected into 293T cells to obtain HIV-2
provirus 7312A. 7×103 TZM-bl cells were plated in 96-well tissue
culture plates and cultured overnight in DMEM supplemented with
10% FBS. 3000 infectious units of HIV-2 were combined in a total
volume of 60 μl with or without a 2× concentration of sCD4 (R&D
Systems) in DMEM with 6% FBS and 80 μg/ml DEAE-dextran. The
concentration of sCD4 was chosen so that the ﬁnal 1× concentration
after the addition of test serum/plasma corresponded to the IC50 of
sCD4 speciﬁc for each virus. After 1 h incubation at 37 °C, an equal
volume of serially diluted test serum/plasma in DMEM containing 6%
FBS and 10% normal human plasma (NHP) was added. The virus±
sCD4+test serum/plasma mixture was incubated for 1 h at 37 °C,
then transferred to the overnight-cultured TZM-bl cells. Media was
removed completely from the adherent TZM-bl cells just before the
addition of the virus±sCD4+test serum/plasma mixture. Controls
included wells without virus (uninfected) and those without serum
(virus control). RLU were calculated for duplicate samples, and 50%
neutralizing titers are reported.
ADCC and antibody-dependent cell-mediated viral inhibition (ADCVI)
Measurement of ADCC activity was performed as previously
described (Gomez-Roman et al., 2005). Human PBMC served as
effectors, whereas SIVmac251 and SIVsmE660 gp120 protein coated CEM-
NKR cells separately served as targets, used at an E:T ratio of 50:1.
ADCC titers are deﬁned as the reciprocal dilution at which the percent
ADCC killing was greater than themean percent killing of the negative
controls plus three standard deviations.
ADCVI activity was assessed as described (Xiao et al., 2010), using
rhesus PBMC as effectors and targets. The latter were infected with
SIVE660 and used at an E:T ratio of 20:1. Serum samples were tested at
a 1:200 dilution.
B cell memory ELISpot
Bone marrow (BM) lymphocytes were isolated for enumeration of
total and SIV251 gp120-speciﬁc IgG secreting memory B cells with or
without prior polyclonal stimulation as described (Brocca-Cofano et
al., submitted). Brieﬂy, lymphocytes were cultured for 3 days in R10
medium alone or with R10 medium supplemented with 1 μg/ml CpG
(ODN-2006), 0.5 μg/ml recombinant human sCD40L (Peprotech), and
50 ng/ml recombinant human IL-21 (Peprotech). The cells were
washed in R10 and antibody secreting cells (ASC) were enumerated
by ELISPOT. Multiscreen 96-well ﬁlter plates (MSIPS4510, Millipore,
Bedford, MA) were activated with 70% ethanol, washed three times
100 L.J. Patterson et al. / Virology 411 (2011) 87–102with PBS, and coated overnight at 4 °C with 100 μl of 10 μg/ml goat
anti-monkey IgG (KPL) to measure total IgG or with 300 ng/well of
gp120 to detect virus-speciﬁc ASC. After washing with R-10, total IgG
plates were blocked with 200 μl/well of R-10 plus a 1/20 dilution of
milk (KPL), while plates for speciﬁc IgG were blocked with R-10 alone
and incubated for 2 h at 37 °C. Uncultured or stimulated BM cells
(2×105 for speciﬁc or 104 for total) were added to wells and
incubated at 37 °C overnight. Speciﬁc IgG plates were washed once
with R-10 and blocked with 200 μl/well of R-10 plus 3% bovine serum
albumin (BSA, fraction V; Sigma) for 2 h at 37 °C. Then, all plates were
washed 4× with PBS containing 0.05% Tween 20 (Sigma) (PBST)
followed by addition of biotinylated goat anti monkey IgG (Rockland)
(1 μg/ml) in PBST+1% FBS for 2 h at 37 °C. After four washes with
PBST, the plates were incubated for 1 h at RT with 5 μg/ml HRP-
conjugated avidin-D (Vector Laboratories, Burlingame, CA) in PBST+
1% FBS. Plates were washed 3× with PBST and 3× with PBS, and
developed using 3 amino-9 ethyl-carbazole (AEC, Sigma). Reactions
were stopped by washing twice with water. Spots were counted using
an automated Elispot reader (Axioplan 2 imaging; Zeiss, Munchen,
Germany). Assays were carried out in triplicate, and data are
represented as the percentage of gp120-speciﬁc ASC relative to the
number of total IgG ASC.
Inhibition of SIV transcytosis
SIV transcytosis across a monolayer of HT-29 intestinal epithelial cells
was performed according to the method of Bomsel (Bomsel, 1997),
modiﬁed as previously described (Hidajat et al., 2009). Rectal secretions
diluted 1:10 were evaluated, and inhibition of SIV transcytosis was
expressed as the percentage of p27 antigen recovered in the basal
chamber in the presence of rectal sample, relative to the amount of p27
antigen recovered in the absence of rectal sample.
Mucosal IgA and IgG binding antibodies
Anti-SIVmac251 gp120 IgA and IgG antibodies in rectal secretions
were measured by ELISA as described (Bertley et al., 2004). Brieﬂy,
Nunc MaxiSorp plates were coated with 100 ng of SIVmac251 gp120
(ABL). After blocking, plates were loaded with serial dilutions of
secretions as well as dilutions of Env-speciﬁc IgA and IgG standards
derived from IgG-depleted pooled serum or puriﬁed serum IgG,
respectively, obtained from SIVmac251-infected macaques and cali-
brated as described (Manrique et al., 2009). Plates were developed
with 0.1 μg/ml HRP-conjugated goat anti-monkey IgA or IgG (Alpha
Diagnostic International, San Antonio, TX) and developed with TMB
substrate, followed by measurement of absorbance at 450 nm. To
account for the variable immunoglobulin concentration in secretions,
the concentration of antigen-speciﬁc IgA or IgG in each secretion was
divided by the total IgA or IgG concentration to obtain speciﬁc activity
(ng of speciﬁc IgA or IgG/μg total IgA or IgG). Total IgA/IgG was
measured by ELISA using plates coated with 1 μg/ml afﬁnity-puriﬁed
goat anti-monkey IgA/IgG antibody (AlphaDiagnostic). The standards
for total IgA/IgG were a dilution series of a normal rhesus macaque
serum containing a known amount of IgA and IgG.
Rhesus macaque microarrays
Intestinal gene expression in rhesus macaques was evaluated
using the rhesus macaque genome GeneChips® (Affymetrix, Santa
Clara, CA) comparable to previously publishedmethods (George et al.,
2003, 2005). Brieﬂy, total RNA was extracted from ﬂash-frozen
biopsies using the RNeasy isolation kit (Qiagen). cDNA was synthe-
sized by reverse transcription, which was then used as a template for
synthesis of cRNA in an in vitro transcription reaction using biotin-
labeled nucleotides. The biotin labeled cRNA was hybridized over-
night (16 h) to the rhesus genome speciﬁc high density oligonucle-otide microarray (Affymetrix) and subsequently stained with a
strepavidin–phycoerythrin conjugate and scannedwith an Affymetrix
3000 scanner. Fluorescence emitted was measured and used to
calculate expression levels of each gene. Expression levels of the
experimental samples were then compared to baseline samples to
generate fold changes. A mean ﬂuorescent intensity ≥1.5-fold above
or below mean baseline was considered signiﬁcantly different
(P≤0.05). Background correction, normalization, and statistical
analyses were performed using dChip (http://biosun1.harvard.edu/
complab/dchip) algorithms. Assignment of genes to functional
categories was performed through annotation of gene lists using the
Affymetrix NetAFFX web interface, the DAVID (http://apps1.niaid.nih.
gov/david) annotation tool, Ingenuity Pathway Analysis (IPA), and
through literature-based classiﬁcation by hand. The entire microarray
data set is deposited at the Gene Expression Omnibus in the National
Center for Biotechnology (accession number GSE23722).
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2010.12.033.
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